Medicenna exited the quarter ended December 31, 2025, with cash and cash equivalents of $10.6 million. Based on the Company’s current operating plan, these funds are expected to be sufficient to fund planned operations into the third quarter of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDNAF:
- Medicenna Therapeutics appoints Richard Sutin, Angelos Georgakis to board
- MDNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Medicenna Maps 2026 Milestones as IL-2 Superkine MDNA11 Delivers Promising Cancer Responses
- Medicenna Targets Pivotal 2026 as IL-2 Superkine Programs Advance Toward Registrational Trials
- Medicenna Therapeutics announces key milestones for 2026